{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-121811","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.486477+00:00","generated_at":"2026-05-15T09:14:59.295432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biomea Fusion reports FY2025 net loss of $61.8M; cash runway into Q1 2027; initiates Phase II trials in diabetes","bullets":["Net loss $61.8M for FY2025 vs $138.4M in FY2024; R&D expenses decreased 47% to $62.0M.","Cash and equivalents $56.2M as of Dec 31, 2025; projected cash runway into Q1 2027.","Initiated Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes; topline data expected Q4 2026.","Phase I trial GLP-131 (BMF-650) for obesity initiated; initial 28-day weight reduction data expected Q2 2026.","Positive 52-week data from COVALENT-111: 1.2% mean HbA1c reduction maintained 9 months off therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-121811","json":"https://secwatch.observer/filing/0001193125-26-121811.json","markdown":"https://secwatch.observer/filing/0001193125-26-121811.md","text":"https://secwatch.observer/filing/0001193125-26-121811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/bmea-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:14:59.295432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2431b29a43bf5f215ccc7fb55f06840fa166baf7","claim":"Biomea Fusion, Inc. reported the year ended December 31, 2024 results: net income net loss of $138.4 million.","evidence_excerpt":"The Company reported a net loss attributable to common stockholders of $61.8 million for the year ended December 31, 2025, which included $9.5 million of stock-based compensation, compared to a net loss of $138.4 million for the same period in 2024, which included $19.1 million of stock-based compensation.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2024"},{"label":"Net income","value":"net loss of $138.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6280ecd375aa4b68ed31648affd7e208a6fad8d2","claim":"Biomea Fusion, Inc. reported the full year ended December 31, 2025 results: net income net loss of $61.8 million.","evidence_excerpt":"Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/0001193125-26-121811-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Net income","value":"net loss of $61.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}